

**REMARKS**

Claims 1-121 are pending in this application, and are subject to restriction. The restriction requirement divides the claims into five groups, as follows:

Group I: claims 1-13, 85-95, 97-106, 110, and 118, drawn to the delivery of a TRPV1 agonist to the skin.

Group II: claims 14-45, 111, and 112, drawn to a method of reducing nerve density.

Group III: claims 46-84, 96, 107-109, and 113, drawn to a method of treating capsaicin responsive conditions.

Group IV: claims 115-117, drawn to a method of ranking a composition based on utility.

Group V: claims 119-121, drawn to a method of increasing a molecule in the skin.

Applicants hereby elect Group I, without traverse. Claims 1-13, 85-95, 97-106, 110, and 118 are readable upon the elected invention. Applicants request examination of the elected subject matter on the merits.

Applicants expressly reserve the right under 35 U.S.C. §121 to file a divisional application directed to the non-elected subject matter during the pendency of this application, or an application claiming priority from this application.

**CONCLUSION**

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 524522001300. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 3, 2008

Respectfully submitted,

By   
Lisa A. ArniiRegistration No.: 48,199  
MORRISON & FOERSTER LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
(650) 813-5674